Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary for 3.4.24.23 extracted from

  • Martinez-Fernandez, A.; Garcia-Albeniz, X.; Pineda, E.; Visa, L.; Gallego, R.; Codony-Servat, J.; Auge, J.M.; Longaron, R.; Gascon, P.; Lacy, A.; Castells, A.; Maurel, J.
    Serum matrilysin levels predict outcome in curatively resected colorectal cancer patients (2009), Ann. Surg. Oncol., 16, 1412-1420.
    View publication on PubMed
Search for more literature for 3.4.24.23

Application

Application Comment Organism
medicine serum matrilysin level predicts recurrence in curatively resected colorectal cancer patients. Patients with matrilysin level higher than the median 4.3 ng/ml are more likely to relapse. Median time to progression in relapsed patients is 8 months if matrilysin is above 4.3 ng/ml and 18 months if matrilysin is below 4.3 ng/ml. Node-negative patients with low matrilysin level have a predicted probability of relapse-free survival at 4 years of 88%; if the matrilysin level is higher than the median value, this probability is 77% Homo sapiens

Organism

Organism UniProt Comment Textmining
Homo sapiens P09237 curatively resected colorectal cancer patients
-

Source Tissue

Source Tissue Comment Organism Textmining